Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309728705> ?p ?o ?g. }
- W4309728705 endingPage "4069" @default.
- W4309728705 startingPage "4059" @default.
- W4309728705 abstract "Patients with myelofibrosis (MF) who discontinue ruxolitinib due to progression/resistance have poor prognoses. JAK inhibitors control symptoms and reduce spleen volumes with limited impact on underlying disease pathophysiology. Murine double minute 2 (MDM2), a negative regulator of p53, is overexpressed in circulating malignant CD34+ MF cells. The oral MDM2 inhibitor navtemadlin (KRT-232) restores p53 activity to drive apoptosis of wild-type TP53 tumor cells by inducing expression of pro-apoptotic Bcl-2 family proteins. Navtemadlin demonstrated promising clinical and disease-modifying activity and acceptable safety in a phase II study in patients with relapsed/refractory MF. The randomized phase III BOREAS study compares the efficacy and safety of navtemadlin to best available therapy in patients with MF that is relapsed/refractory to JAK inhibitor treatment.Myelofibrosis (MF) is a rare blood cancer that disrupts normal blood cell production and causes fibrosis (tissue thickening/scarring) in bone marrow, reduced red blood cells in the circulation, and an enlarged spleen. Although currently approved treatments can help relieve some effects, they have limited impact on the underlying cause of the disease. Navtemadlin is a new therapy that inhibits a protein frequently overexpressed in cancer cells found in MF patients called murine double minute 2 (MDM2), which regulates a common tumor suppressor protein called p53. By inhibiting MDM2, navtemadlin restores normal p53 function and its ability to kill MF cancer cells. BOREAS is a large clinical study of navtemadlin for MF patients whose disease is not responding to current therapy." @default.
- W4309728705 created "2022-11-29" @default.
- W4309728705 creator A5005641797 @default.
- W4309728705 creator A5008609620 @default.
- W4309728705 creator A5024649910 @default.
- W4309728705 creator A5036657478 @default.
- W4309728705 creator A5041951303 @default.
- W4309728705 creator A5046772202 @default.
- W4309728705 creator A5046857415 @default.
- W4309728705 creator A5049461057 @default.
- W4309728705 creator A5051485142 @default.
- W4309728705 creator A5066408727 @default.
- W4309728705 creator A5072336042 @default.
- W4309728705 creator A5073159044 @default.
- W4309728705 creator A5074629157 @default.
- W4309728705 creator A5085521139 @default.
- W4309728705 date "2022-12-01" @default.
- W4309728705 modified "2023-10-16" @default.
- W4309728705 title "BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis" @default.
- W4309728705 cites W1650797637 @default.
- W4309728705 cites W1989336431 @default.
- W4309728705 cites W2002936090 @default.
- W4309728705 cites W2008135652 @default.
- W4309728705 cites W2012796327 @default.
- W4309728705 cites W2049965335 @default.
- W4309728705 cites W2052451894 @default.
- W4309728705 cites W2070990294 @default.
- W4309728705 cites W2090240238 @default.
- W4309728705 cites W2094916879 @default.
- W4309728705 cites W2105414227 @default.
- W4309728705 cites W2127559749 @default.
- W4309728705 cites W2134919790 @default.
- W4309728705 cites W2147318282 @default.
- W4309728705 cites W2339658711 @default.
- W4309728705 cites W2559174059 @default.
- W4309728705 cites W2731573311 @default.
- W4309728705 cites W2732945346 @default.
- W4309728705 cites W2739409493 @default.
- W4309728705 cites W2752942423 @default.
- W4309728705 cites W2768672347 @default.
- W4309728705 cites W2799932402 @default.
- W4309728705 cites W2903942306 @default.
- W4309728705 cites W2910046601 @default.
- W4309728705 cites W2911435756 @default.
- W4309728705 cites W2955077735 @default.
- W4309728705 cites W2965547724 @default.
- W4309728705 cites W3012454590 @default.
- W4309728705 cites W3029377693 @default.
- W4309728705 cites W3045198911 @default.
- W4309728705 cites W3095913618 @default.
- W4309728705 cites W3105658552 @default.
- W4309728705 cites W3120572889 @default.
- W4309728705 cites W3166268434 @default.
- W4309728705 cites W3167008187 @default.
- W4309728705 cites W3186480219 @default.
- W4309728705 cites W3213980533 @default.
- W4309728705 doi "https://doi.org/10.2217/fon-2022-0901" @default.
- W4309728705 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36416118" @default.
- W4309728705 hasPublicationYear "2022" @default.
- W4309728705 type Work @default.
- W4309728705 citedByCount "9" @default.
- W4309728705 countsByYear W43097287052023 @default.
- W4309728705 crossrefType "journal-article" @default.
- W4309728705 hasAuthorship W4309728705A5005641797 @default.
- W4309728705 hasAuthorship W4309728705A5008609620 @default.
- W4309728705 hasAuthorship W4309728705A5024649910 @default.
- W4309728705 hasAuthorship W4309728705A5036657478 @default.
- W4309728705 hasAuthorship W4309728705A5041951303 @default.
- W4309728705 hasAuthorship W4309728705A5046772202 @default.
- W4309728705 hasAuthorship W4309728705A5046857415 @default.
- W4309728705 hasAuthorship W4309728705A5049461057 @default.
- W4309728705 hasAuthorship W4309728705A5051485142 @default.
- W4309728705 hasAuthorship W4309728705A5066408727 @default.
- W4309728705 hasAuthorship W4309728705A5072336042 @default.
- W4309728705 hasAuthorship W4309728705A5073159044 @default.
- W4309728705 hasAuthorship W4309728705A5074629157 @default.
- W4309728705 hasAuthorship W4309728705A5085521139 @default.
- W4309728705 hasBestOaLocation W43097287051 @default.
- W4309728705 hasConcept C121608353 @default.
- W4309728705 hasConcept C126322002 @default.
- W4309728705 hasConcept C142424586 @default.
- W4309728705 hasConcept C142724271 @default.
- W4309728705 hasConcept C143998085 @default.
- W4309728705 hasConcept C190283241 @default.
- W4309728705 hasConcept C2776112149 @default.
- W4309728705 hasConcept C2776192174 @default.
- W4309728705 hasConcept C2780007613 @default.
- W4309728705 hasConcept C2780076729 @default.
- W4309728705 hasConcept C502942594 @default.
- W4309728705 hasConcept C55493867 @default.
- W4309728705 hasConcept C71924100 @default.
- W4309728705 hasConcept C86803240 @default.
- W4309728705 hasConcept C87355193 @default.
- W4309728705 hasConcept C96232424 @default.
- W4309728705 hasConceptScore W4309728705C121608353 @default.
- W4309728705 hasConceptScore W4309728705C126322002 @default.
- W4309728705 hasConceptScore W4309728705C142424586 @default.
- W4309728705 hasConceptScore W4309728705C142724271 @default.